secwatch / observer
8-K filed January 16, 2025, 6:59 PM ET ticker IVF CIK 0001417926
other material confidence high sentiment neutral materiality 0.80

NAYA Biosciences Prices $9.5M Public Offering and Receives Nasdaq Notice for Missing Annual Meeting

INVO Fertility, Inc.

item 1.01item 2.04item 3.01item 7.01item 9.01

Machine-readable event card

schema_version
secwatch.filing_event.v1
accession
0001493152-25-002543
form_type
8-K
ticker
IVF
cik
0001417926
company_name
INVO Fertility, Inc.
filed_at
2025-01-16T23:59:59+00:00
discovered_at
2026-05-14T18:03:03.577173+00:00
generated_at
2026-05-27T23:54:46.162946+00:00
sec_items
["1.01", "2.04", "3.01", "7.01", "9.01"]
event_type
other_material
sentiment
neutral
materiality_score
0.8
calibrated_materiality_score
0.8
confidence
high
secwatch_canonical_url
https://secwatch.observer/filing/0001493152-25-002543
json_url
https://secwatch.observer/filing/0001493152-25-002543.json
markdown_url
https://secwatch.observer/filing/0001493152-25-002543.md
text_url
https://secwatch.observer/filing/0001493152-25-002543.txt
edgar_index_url
https://www.sec.gov/Archives/edgar/data/1417926/000149315225002543/0001493152-25-002543-index.htm
edgar_primary_document_url
https://www.sec.gov/Archives/edgar/data/1417926/000149315225002543/form8-k.htm
generated_by_model
deepseek-v4-flash:cloud
review_status
machine_generated
human_reviewed
false
corrected
false
correction_note
null
correction_timestamp
null
superseded_by
null
JSON Markdown Plain text

Source-grounded claims

2edaebdb18ddd265806461125bd13ef97d343386

INVO Fertility, Inc. received a nasdaq deficiency notice notice regarding other (rules 5620(a), 5801(s)(2)(G)).

January 10, 2025, the Company received notice (the “Notice”) from the staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it no longer complies with Nasdaq Listing Rules 5620(a) and 58

SEC 8-K Item 3.01 confidence 0.9 SEC evidence

Comparable filings

ISPC

iSpecimen prices $2.5M private placement at $5.12/share; regains Nasdaq minimum bid price compliance

iSpecimen Inc. May 13, 2026, 5:00 PM ET other_material Items 1.01, 3.01, 3.02, 7.01, 8.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 1.01, 3.01, 7.01, 9.01 same event type: other_material similar materiality

This filing

January 10, 2025, the Company received notice (the “Notice”) from the staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it no longer complies with Nasdaq Listing Rules 5620(a) and 58

Comparable filing

minimum $1.00 per share required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”) for the prior 30 consecutive business days. On May 12, 2026

Filing page SEC filing

AGAE

AIFA gets Nasdaq delisting notice for late filings; later files FY 2025 10-K

Allied Gaming & Entertainment Inc. May 21, 2026, 9:40 PM ET other_material Items 3.01, 7.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01, 7.01, 9.01 same event type: other_material similar materiality

This filing

January 10, 2025, the Company received notice (the “Notice”) from the staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it no longer complies with Nasdaq Listing Rules 5620(a) and 58

Comparable filing

May 19, 2026, All In FutureTech Alliance, Inc. (formerly known as Allied Gaming & Entertainment Inc., the “Company”) received a deficiency letter (the “Letter”) from the Listing Qualifications Department (the “Staff”) of

Filing page SEC filing

PMI

Picard Medical Q1 revenue up 85% to $1.2M; reports $1.4M negative equity, NYSE listing notices

Picard Medical, Inc. May 21, 2026, 4:15 PM ET other_material Items 2.02, 3.01, 7.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01, 7.01, 9.01 same event type: other_material similar materiality

This filing

January 10, 2025, the Company received notice (the “Notice”) from the staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it no longer complies with Nasdaq Listing Rules 5620(a) and 58

Comparable filing

reviously disclosed, on May 8, 2026, the Company received a notice that it was not in compliance with Section 1003(a)(ii) (the “May 8 Notice,” and together with the May 15 Notice, the “ Notices ”). In connection with the

Filing page SEC filing

BKYI

BIO-key receives Nasdaq delisting notice; stock to move to OTC Markets on May 13

BIO KEY INTERNATIONAL INC May 12, 2026, 4:46 PM ET other_material Items 3.01, 7.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01, 7.01, 9.01 same event type: other_material similar materiality

This filing

January 10, 2025, the Company received notice (the “Notice”) from the staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it no longer complies with Nasdaq Listing Rules 5620(a) and 58

Comparable filing

May 6, 2026, BIO-key International, Inc. (the “ Company ”) received notice from the staff of The Nasdaq Stock Market, LLC (“ Nasdaq ”) stating that the Company had not regained compliance with Nasdaq Listing Rule 5550(a)

Filing page SEC filing

PMI

Picard Medical raises $5M in public offering, receives NYSE American delisting notice for low equity

Picard Medical, Inc. May 11, 2026, 5:08 PM ET other_material Items 1.01, 3.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 1.01, 3.01, 9.01 same event type: other_material similar materiality

This filing

January 10, 2025, the Company received notice (the “Notice”) from the staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it no longer complies with Nasdaq Listing Rules 5620(a) and 58

Comparable filing

May 8, 2026, the Company received a written notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) indicating that the Company is not in compliance with the NYSE American continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company Guide (the “Company Guide”) requiring a company to have stockholders’ equity of at least $4.0 million if it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. The Notice states that the Company reported a stockholders’ equity of approximately $3.8 million as of

Filing page SEC filing

DRCT

DRCT enters $50M equity line with Roth, terminates New Circle ELOC, receives Nasdaq delisting notice

Direct Digital Holdings, Inc. April 28, 2026, 7:59 PM ET other_material Items 1.01, 1.02, 3.01, 3.03, 5.03, 9.01

same fact type: exchange_compliance_notice same SEC item: 1.01, 3.01, 9.01 same event type: other_material similar materiality

This filing

January 10, 2025, the Company received notice (the “Notice”) from the staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it no longer complies with Nasdaq Listing Rules 5620(a) and 58

Comparable filing

April 23, 2026, the Company received an Additional Staff Delisting Determination Letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”), notifying the Company that it is not in comp

Filing page SEC filing

ADTX

Aditxt receives Nasdaq deficiency for negative equity; delisting hearing set for June 11

Aditxt, Inc. May 29, 2026, 4:21 PM ET other_material Items 3.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01, 9.01 same event type: other_material similar materiality

This filing

January 10, 2025, the Company received notice (the “Notice”) from the staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it no longer complies with Nasdaq Listing Rules 5620(a) and 58

Comparable filing

May 27, 2026, Aditxt, Inc. (the “Company”) received a letter (the “Letter”) from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based on the stockholders’ equity of $(35,174,386) reported in the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2026 (the “Form 10-Q”), the Company no longer satisfies the minimum stockholders’ equity requirement of $2,500,000 for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(1) (the “Stockholders’ Equity Requirement”). The Letter further

Filing page SEC filing

LIMN

Liminatus Pharma receives Nasdaq delisting notice; appeals filed

Liminatus Pharma, Inc. May 27, 2026, 4:30 PM ET other_material Items 3.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01, 9.01 same event type: other_material similar materiality

This filing

January 10, 2025, the Company received notice (the “Notice”) from the staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it no longer complies with Nasdaq Listing Rules 5620(a) and 58

Comparable filing

May 20, 2026, the Company received a notice from Nasdaq stating that the Company had not regained compliance with the MVLS Rule and the MVPHS Rule. Accordingly, its securities will be delisted from The Nasdaq Global Mark

Filing page SEC filing

Source: SEC EDGAR
accession 0001493152-25-002543
view filing index on sec.gov
view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.